NO990328D0 - Fuserte polypeptider som omfatter et IGE-bindingsdomene og en HSA-komponent, og deres diagnostiske og terapeutiske bruk - Google Patents

Fuserte polypeptider som omfatter et IGE-bindingsdomene og en HSA-komponent, og deres diagnostiske og terapeutiske bruk

Info

Publication number
NO990328D0
NO990328D0 NO990328A NO990328A NO990328D0 NO 990328 D0 NO990328 D0 NO 990328D0 NO 990328 A NO990328 A NO 990328A NO 990328 A NO990328 A NO 990328A NO 990328 D0 NO990328 D0 NO 990328D0
Authority
NO
Norway
Prior art keywords
diagnostic
binding domain
therapeutic uses
ige binding
fused polypeptides
Prior art date
Application number
NO990328A
Other languages
English (en)
Other versions
NO323611B1 (no
NO990328L (no
Inventor
Mary Ellen Digan
Philip Lake
Hermann Gram
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO990328D0 publication Critical patent/NO990328D0/no
Publication of NO990328L publication Critical patent/NO990328L/no
Publication of NO323611B1 publication Critical patent/NO323611B1/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/64General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76Albumins
    • C07K14/765Serum albumin, e.g. HSA
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/70535Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00Genetically modified animals
    • A01K2217/05Animals comprising random inserted nucleic acids (transgenic)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NO19990328A 1996-07-26 1999-01-25 Fusjonspolypeptidisolert polynukleotid, fremgangsmate for fremstilling, og vektorer, samt farmasoytisk sammensetning og anvendelse av fusjonspolypeptider for fremstilling av medikament for behandling av IgE- eller IgE-reseptormedierte forstyrrelser NO323611B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69021696A 1996-07-26 1996-07-26
PCT/EP1997/004066 WO1998004718A1 (en) 1996-07-26 1997-07-25 Fusion polypeptides comprising an ige-binding domain and a hsa component, and their diagnostic and therapeutic uses

Publications (3)

Publication Number Publication Date
NO990328D0 true NO990328D0 (no) 1999-01-25
NO990328L NO990328L (no) 1999-02-19
NO323611B1 NO323611B1 (no) 2007-06-18

Family

ID=24771594

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19990328A NO323611B1 (no) 1996-07-26 1999-01-25 Fusjonspolypeptidisolert polynukleotid, fremgangsmate for fremstilling, og vektorer, samt farmasoytisk sammensetning og anvendelse av fusjonspolypeptider for fremstilling av medikament for behandling av IgE- eller IgE-reseptormedierte forstyrrelser

Country Status (28)

Country Link
EP (1) EP0917581B1 (no)
JP (1) JP3681402B2 (no)
KR (1) KR100502879B1 (no)
CN (1) CN1146664C (no)
AR (1) AR008077A1 (no)
AT (1) ATE383429T1 (no)
AU (1) AU722069B2 (no)
BR (1) BR9710605A (no)
CA (1) CA2261562C (no)
CO (1) CO4650184A1 (no)
CZ (1) CZ297634B6 (no)
DE (1) DE69738452T2 (no)
ES (1) ES2300114T3 (no)
HK (1) HK1020352A1 (no)
ID (1) ID19420A (no)
IL (2) IL128094A0 (no)
MY (1) MY120425A (no)
NO (1) NO323611B1 (no)
NZ (1) NZ333908A (no)
PE (1) PE99498A1 (no)
PL (1) PL189415B1 (no)
PT (1) PT917581E (no)
RU (1) RU2209211C2 (no)
SK (1) SK7799A3 (no)
TR (1) TR199900155T2 (no)
TW (1) TW565571B (no)
WO (1) WO1998004718A1 (no)
ZA (1) ZA976666B (no)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1056471A4 (en) * 1998-01-29 2001-05-30 Tanox Inc TREATMENT OF ATOPIC DERMATITIS USING IgE ANTAGONISTS
JP4087563B2 (ja) 1998-06-15 2008-05-21 ジーティーシー バイオセラピューティックス インコーポレイテッド エリスロポエチン類似体−ヒト血清アルブミン融合物
EP1208194A2 (en) * 1999-08-09 2002-05-29 Genaissance Pharmaceuticals, Inc. Drug target isogenes: polymorphisms in the immunoglobulin e receptor i alpha subunit gene
DE10026998A1 (de) * 2000-05-31 2001-12-13 Fresenius Kabi De Gmbh Verfahren zur Herstellung einer kosmetischen Zusammensetzung, die humanes Serum Albumin umfasst, welches aus transgenen nicht-menschlichen Säugern erhalten wurde
IL155812A0 (en) * 2000-12-07 2003-12-23 Lilly Co Eli Glp-1 fusion proteins
TW200526779A (en) * 2001-02-08 2005-08-16 Wyeth Corp Modified and stabilized GDF propeptides and uses thereof
EP1463751B1 (en) 2001-12-21 2013-05-22 Human Genome Sciences, Inc. Albumin fusion proteins
US8927694B2 (en) 2008-11-18 2015-01-06 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof
US8962274B2 (en) 2009-02-27 2015-02-24 Novartis Ag Methods for selecting eukaryotic cells expressing a heterologous protein
WO2012169735A2 (ko) * 2011-06-07 2012-12-13 (주)네오팜 FCεRI의 수용성 단편을 포함하는 복합체 및 이를 포함하는 IGE 매개 알레르기성 질환 치료용 조성물
RU2506271C2 (ru) * 2011-06-22 2014-02-10 Учреждение Российской Академии Медицинских Наук Научно-исследовательский институт экспериментальной медицины Северо-западного отделения РАМН (НИИЭМ СЗО РАМН) РЕКОМБИНАНТНЫЙ ПОЛИПЕПТИД А2, СЕЛЕКТИВНО СВЯЗЫВАЮЩИЙ HSA, РЕКОМБИНАНТНАЯ ДНК pa2, КОДИРУЮЩАЯ HSA-СВЯЗЫВАЮЩУЮ ЧАСТЬ ПОЛИПЕПТИДА A2, ЕГО ПРОДУЦЕНТ - РЕКОМБИНАНТНЫЙ ШТАММ Escherichia coli M15-A2, СОДЕРЖАЩИЙ РЕКОМБИНАНТНУЮ ПЛАЗМИДНУЮ ДНК pQE 32-pa2, ОБЕСПЕЧИВАЮЩУЮ ПОЛУЧЕНИЕ ПОЛИПЕПТИДА A2 И ПРИМЕНЕНИЕ ПОЛИПЕПТИДА А2 ДЛЯ ДИАГНОСТИКИ МИКРОАЛЬБУМИНУРИИ И ВЫДЕЛЕНИЯ HSA ИЗ СЫВОРОТКИ КРОВИ
US9345766B2 (en) 2012-08-30 2016-05-24 Merrimack Pharmaceuticals, Inc. Combination therapies comprising anti-ERBB3 agents
US20180139938A1 (en) * 2015-05-04 2018-05-24 Laboratoire Français du Fractionnement et des, Biotechnologies Transgenic production of fc fusion proteins
EP3192806A1 (en) 2016-01-13 2017-07-19 Affiris AG Alpha chain of the high-affinity ige receptor (fceria)
JP7127859B2 (ja) * 2016-11-09 2022-08-30 ノース カロライナ ステート ユニバーシティ キメラタンパク質を用いたアレルギー疾患の治療
EP3998277A4 (en) * 2019-07-08 2023-11-22 Progen Co., Ltd. NOVEL IL-10 PROTEIN VARIANT AND THEREOF USE
CN111773392B (zh) * 2020-05-25 2023-04-07 河南省生物工程技术研究中心 一种人血白蛋白/寡核苷酸纳米颗粒及其制备方法和用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4962035A (en) * 1987-12-01 1990-10-09 President And Fellows Of Harvard College DNA encoding IgE receptor alpha-subunit or fragment thereof
GB8909916D0 (en) * 1989-04-29 1989-06-14 Delta Biotechnology Ltd Polypeptides
CA2059842A1 (en) * 1991-02-11 1992-08-12 Richard A. Chizzonite Ige-receptor-antibodies

Also Published As

Publication number Publication date
KR100502879B1 (ko) 2005-07-25
DE69738452T2 (de) 2008-12-24
KR20000029563A (ko) 2000-05-25
PT917581E (pt) 2008-04-11
AR008077A1 (es) 1999-12-09
EP0917581B1 (en) 2008-01-09
MY120425A (en) 2005-10-31
HK1020352A1 (en) 2000-04-14
IL128094A (en) 2006-08-20
WO1998004718A1 (en) 1998-02-05
NO323611B1 (no) 2007-06-18
BR9710605A (pt) 1999-08-17
CO4650184A1 (es) 1998-09-03
ES2300114T3 (es) 2008-06-01
JP2000516089A (ja) 2000-12-05
ZA976666B (en) 1999-01-25
TW565571B (en) 2003-12-11
JP3681402B2 (ja) 2005-08-10
PE99498A1 (es) 1999-01-21
EP0917581A1 (en) 1999-05-26
ATE383429T1 (de) 2008-01-15
CZ24699A3 (cs) 1999-04-14
IL128094A0 (en) 1999-11-30
CN1229439A (zh) 1999-09-22
AU722069B2 (en) 2000-07-20
CA2261562C (en) 2011-04-05
DE69738452D1 (de) 2008-02-21
PL331356A1 (en) 1999-07-05
NZ333908A (en) 1999-10-28
TR199900155T2 (xx) 2000-08-21
AU4202597A (en) 1998-02-20
CN1146664C (zh) 2004-04-21
RU2209211C2 (ru) 2003-07-27
ID19420A (id) 1998-07-09
NO990328L (no) 1999-02-19
SK7799A3 (en) 1999-07-12
PL189415B1 (pl) 2005-08-31
CA2261562A1 (en) 1998-02-05
CZ297634B6 (cs) 2007-02-21

Similar Documents

Publication Publication Date Title
NO990328D0 (no) Fuserte polypeptider som omfatter et IGE-bindingsdomene og en HSA-komponent, og deres diagnostiske og terapeutiske bruk
EE05538B1 (et) Interleukiin-18 seostuvad valgud, nende valmistamine ja kasutamine
DK0674890T3 (da) Elastiske og varmeforseglelige, medicinske bind
NO972983D0 (no) Sulfonamider og deres anvendelse
NO983965D0 (no) Polymer-organoleire-kompositter og deres fremstilling
DK0835266T3 (da) Modificerede/kimære superantigener og deres anvendelse
WO2001053354A3 (en) Methods for treating tumors using a fusion protein comprising il-2- polypeptides and p185-specific binding molecules
ID18741A (id) Zat nikotinat dalam terapi
NO971560L (no) Piezoelektrisk svingeelement og kretskomponent med slikt element
DK0906529T3 (da) Aktiveringsstift
NO20001934D0 (no) 3-Substituerte tetrahydropyridopyrimidinon-derivater, deres fremstilling og anvendelse
DE69705017T2 (de) Medikamente bindendes Protein
ID21034A (id) Protein kinase dan penggunaannya
NO995308D0 (no) Sammensetning og fremgangsmÕter som anvender en eutomer
DE69837507D1 (de) Humanes Hedgehog-Protein
DK1032559T3 (da) Aminoalkylphenolderivater til behandling af depression og hukommelsessvigt
NO984921D0 (no) Tienopyridinderivater og deres anvendelse
NO20005547D0 (no) Myelinbasiske proteinpeptider og anvendelser derav
NO990303D0 (no) Lipidbindende proteiner og deres terapeutiske og diagnostiske anvendelse
AU1683799A (en) Heat shock transcription factor-binding protein
NO970165D0 (no) Kortikotropin frigivningsfaktor-bindingsprotein inhibitorer og deres anvendelse
ES1037227Y (es) Panel calefactor perfeccionado.
DK1092027T3 (da) Terapeutiske og diagnostiske domæne 1-beta 2-GPI-polypeptider og fremgangsmåder til anvendelse af samme
HUP9903094A3 (en) Fusion polypeptides comprising an ige-binding domain and a hsa component, and their diagnostic and therapeutic uses
DK0907370T3 (da) HLA-A2.1-Bindingspeptider og deres anvendelser

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees